NO318575B1 - Stabile sammensetninger som omfatter levosimendan og alginsyre - Google Patents
Stabile sammensetninger som omfatter levosimendan og alginsyre Download PDFInfo
- Publication number
- NO318575B1 NO318575B1 NO20005312A NO20005312A NO318575B1 NO 318575 B1 NO318575 B1 NO 318575B1 NO 20005312 A NO20005312 A NO 20005312A NO 20005312 A NO20005312 A NO 20005312A NO 318575 B1 NO318575 B1 NO 318575B1
- Authority
- NO
- Norway
- Prior art keywords
- levosimendan
- composition
- alginic acid
- stated
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title claims abstract description 27
- 229960000692 levosimendan Drugs 0.000 title claims abstract description 27
- 239000000783 alginic acid Substances 0.000 title claims abstract description 13
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 13
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 13
- 229960001126 alginic acid Drugs 0.000 title claims abstract description 13
- 150000004781 alginic acids Chemical class 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 abstract description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 14
- 239000000654 additive Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920003093 Methocel™ K100 LV Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 1
- -1 Avicel PHI01 Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Jellies, Jams, And Syrups (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI980902A FI980902A7 (fi) | 1998-04-23 | 1998-04-23 | Levosimendaanin stabiileja koostumuksia |
| PCT/FI1999/000331 WO1999055337A1 (en) | 1998-04-23 | 1999-04-23 | Stabile compositions comprising levosimendan and alginic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005312D0 NO20005312D0 (no) | 2000-10-20 |
| NO20005312L NO20005312L (no) | 2000-11-21 |
| NO318575B1 true NO318575B1 (no) | 2005-04-11 |
Family
ID=8551576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005312A NO318575B1 (no) | 1998-04-23 | 2000-10-20 | Stabile sammensetninger som omfatter levosimendan og alginsyre |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6531458B1 (cs) |
| EP (1) | EP1079834B1 (cs) |
| JP (1) | JP4475809B2 (cs) |
| KR (1) | KR100590622B1 (cs) |
| CN (1) | CN1165309C (cs) |
| AT (1) | ATE231395T1 (cs) |
| AU (1) | AU756338B2 (cs) |
| BG (1) | BG64766B1 (cs) |
| BR (1) | BR9909867A (cs) |
| CA (1) | CA2329232C (cs) |
| CZ (1) | CZ290911B6 (cs) |
| DE (1) | DE69905034T2 (cs) |
| DK (1) | DK1079834T3 (cs) |
| EA (1) | EA002428B1 (cs) |
| EE (1) | EE04143B1 (cs) |
| ES (1) | ES2191426T3 (cs) |
| FI (1) | FI980902A7 (cs) |
| GE (1) | GEP20032942B (cs) |
| HR (1) | HRP20000703B1 (cs) |
| HU (1) | HUP0105446A3 (cs) |
| ID (1) | ID26650A (cs) |
| IL (2) | IL138950A0 (cs) |
| MX (1) | MXPA00010368A (cs) |
| NO (1) | NO318575B1 (cs) |
| NZ (1) | NZ507455A (cs) |
| PL (1) | PL192274B1 (cs) |
| PT (1) | PT1079834E (cs) |
| RS (1) | RS49955B (cs) |
| SK (1) | SK284600B6 (cs) |
| TR (1) | TR200003101T2 (cs) |
| WO (1) | WO1999055337A1 (cs) |
| ZA (1) | ZA200005630B (cs) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI980901A7 (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
| FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
| FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
| WO2002064120A1 (fr) * | 2001-02-13 | 2002-08-22 | Taisho Pharmaceutical Co., Ltd. | Preparations de gel a usage interne |
| JP2008533109A (ja) * | 2005-03-14 | 2008-08-21 | オリオン コーポレーション | 利尿を促進するための複合治療 |
| CN108289832B (zh) * | 2015-11-06 | 2021-08-31 | 卡利努法姆股份有限公司 | 用于以输注或注射形式进行静脉给药的左西孟旦以及输注浓缩液的改善配方 |
| WO2021126884A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1509866A (en) | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
| AU555304B2 (en) * | 1982-04-05 | 1986-09-18 | Merck Sharp & Dohme Limited | Stabilization of drugs in alginic acid and magnesium hydroxide granules |
| EP0123291A2 (en) | 1983-04-20 | 1984-10-31 | Kyowa Hakko Kogyo Co., Ltd. | Method for stabilizing interferon |
| US4906630A (en) * | 1985-11-22 | 1990-03-06 | Rorer Pharmaceutical Corporation | Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds |
| US4716042A (en) | 1986-06-16 | 1987-12-29 | American Home Products Corporation | Stabilized coated aspirin tablets |
| GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
| GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
| FI973804A7 (fi) * | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
-
1998
- 1998-04-23 FI FI980902A patent/FI980902A7/fi unknown
-
1999
- 1999-04-23 KR KR1020007011789A patent/KR100590622B1/ko not_active Expired - Fee Related
- 1999-04-23 MX MXPA00010368A patent/MXPA00010368A/es active IP Right Grant
- 1999-04-23 PT PT99916943T patent/PT1079834E/pt unknown
- 1999-04-23 SK SK1555-2000A patent/SK284600B6/sk not_active IP Right Cessation
- 1999-04-23 US US09/673,793 patent/US6531458B1/en not_active Expired - Fee Related
- 1999-04-23 PL PL343722A patent/PL192274B1/pl not_active IP Right Cessation
- 1999-04-23 EA EA200001097A patent/EA002428B1/ru not_active IP Right Cessation
- 1999-04-23 ID IDW20002368A patent/ID26650A/id unknown
- 1999-04-23 ES ES99916943T patent/ES2191426T3/es not_active Expired - Lifetime
- 1999-04-23 NZ NZ507455A patent/NZ507455A/en unknown
- 1999-04-23 RS YUP-640/00A patent/RS49955B/sr unknown
- 1999-04-23 GE GEAP19995638A patent/GEP20032942B/en unknown
- 1999-04-23 DK DK99916943T patent/DK1079834T3/da active
- 1999-04-23 JP JP2000545535A patent/JP4475809B2/ja not_active Expired - Lifetime
- 1999-04-23 HR HR20000703A patent/HRP20000703B1/xx not_active IP Right Cessation
- 1999-04-23 EP EP99916943A patent/EP1079834B1/en not_active Expired - Lifetime
- 1999-04-23 IL IL13895099A patent/IL138950A0/xx active IP Right Grant
- 1999-04-23 TR TR2000/03101T patent/TR200003101T2/xx unknown
- 1999-04-23 DE DE69905034T patent/DE69905034T2/de not_active Expired - Lifetime
- 1999-04-23 WO PCT/FI1999/000331 patent/WO1999055337A1/en active IP Right Grant
- 1999-04-23 CA CA002329232A patent/CA2329232C/en not_active Expired - Fee Related
- 1999-04-23 CN CNB998053805A patent/CN1165309C/zh not_active Expired - Fee Related
- 1999-04-23 AT AT99916943T patent/ATE231395T1/de not_active IP Right Cessation
- 1999-04-23 BR BR9909867-9A patent/BR9909867A/pt not_active Application Discontinuation
- 1999-04-23 EE EEP200000616A patent/EE04143B1/xx not_active IP Right Cessation
- 1999-04-23 CZ CZ20003779A patent/CZ290911B6/cs not_active IP Right Cessation
- 1999-04-23 HU HU0105446A patent/HUP0105446A3/hu unknown
- 1999-04-23 AU AU35248/99A patent/AU756338B2/en not_active Ceased
-
2000
- 2000-10-11 IL IL138950A patent/IL138950A/en not_active IP Right Cessation
- 2000-10-12 ZA ZA200005630A patent/ZA200005630B/en unknown
- 2000-10-20 NO NO20005312A patent/NO318575B1/no not_active IP Right Cessation
- 2000-11-17 BG BG104958A patent/BG64766B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100348842B1 (ko) | 염기성물질로안정화된약제학적조성물 | |
| ES2231873T3 (es) | Procedimiento de preparacion de formas solidas de valsartan para dosificacion oral. | |
| KR100202154B1 (ko) | 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제 | |
| FI101040B (fi) | Menetelmä sentraalisten dopamiininpuutostilojen hoitoon tarkoitetun, p eroraalisesti annettavan lääkemuodon valmistamiseksi | |
| PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
| KR970069038A (ko) | 시사프라이드의 즉시 방출형 ph-비의존성 고형 제제 | |
| EP1035838A1 (en) | Pharmaceutical suspension tablet compositions | |
| KR20010086062A (ko) | 고가용성 약물용 서방성 메트리스 시스템 | |
| AU687744B2 (en) | More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent | |
| KR20050043765A (ko) | 방출 제어형 메트포르민 정제 | |
| NO318575B1 (no) | Stabile sammensetninger som omfatter levosimendan og alginsyre | |
| JP2014012660A (ja) | ロキソプロフェン含有医薬組成物 | |
| JPH0140009B2 (cs) | ||
| EP1404303A1 (en) | Stable pharmaceutical compositions containing pravastatin | |
| JPH10226644A (ja) | 医薬組成物 | |
| HK1031998B (en) | Stable compositions comprising levosimendan and alginic acid | |
| JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
| CS276556B6 (en) | Pharmaceutical with a controllable bio-disposal of active component | |
| HK136097A (en) | Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |